ATE150750T1 - Fumagillol-derivate - Google Patents
Fumagillol-derivateInfo
- Publication number
- ATE150750T1 ATE150750T1 AT89116052T AT89116052T ATE150750T1 AT E150750 T1 ATE150750 T1 AT E150750T1 AT 89116052 T AT89116052 T AT 89116052T AT 89116052 T AT89116052 T AT 89116052T AT E150750 T1 ATE150750 T1 AT E150750T1
- Authority
- AT
- Austria
- Prior art keywords
- substituted
- group
- optionally
- carbamoyl
- compound
- Prior art date
Links
- 150000002284 fumagillol derivatives Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000006020 2-methyl-1-propenyl group Chemical group 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 abstract 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 1
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 125000003435 aroyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 1
- -1 cyano, carbamoyl Chemical group 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 abstract 1
- 125000006678 phenoxycarbonyl group Chemical group 0.000 abstract 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/28—Ethers with hydroxy compounds containing oxirane rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epoxy Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21928788 | 1988-09-01 | ||
| JP5353789 | 1989-03-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE150750T1 true ATE150750T1 (de) | 1997-04-15 |
Family
ID=26394244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT89116052T ATE150750T1 (de) | 1988-09-01 | 1989-08-31 | Fumagillol-derivate |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US5698586A (de) |
| EP (2) | EP0682020A1 (de) |
| KR (1) | KR0138530B1 (de) |
| AT (1) | ATE150750T1 (de) |
| DE (1) | DE68927904T2 (de) |
| ES (1) | ES2099064T3 (de) |
| GR (1) | GR3023745T3 (de) |
Families Citing this family (90)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH26256A (en) * | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
| US6017954A (en) * | 1989-08-10 | 2000-01-25 | Children's Medical Center Corp. | Method of treating tumors using O-substituted fumagillol derivatives |
| TW282399B (de) * | 1990-05-25 | 1996-08-01 | Takeda Pharm Industry Co Ltd | |
| DE69114782T2 (de) * | 1990-08-08 | 1996-04-18 | Takeda Chemical Industries Ltd | Intravaskulär embolisierendes Mittel mit Gehalt an einem die Angiogenesis hemmenden Stoff. |
| NZ240214A (en) | 1990-10-16 | 1993-02-25 | Takeda Chemical Industries Ltd | Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs |
| DE69231457T2 (de) * | 1991-06-21 | 2001-05-23 | Takeda Chemical Industries Ltd | Zyklodextrin-Zusammensetzung enthaltend Fumagillol-Derivate |
| US6903084B2 (en) | 1991-08-28 | 2005-06-07 | Sterix Limited | Steroid sulphatase inhibitors |
| US6011024A (en) | 1991-08-28 | 2000-01-04 | Imperial College Of Science Technology & Medicine | Steroid sulphatase inhibitors |
| US6476011B1 (en) | 1991-08-28 | 2002-11-05 | Sterix Limited | Methods for introducing an estrogenic compound |
| EP0582459B1 (de) | 1992-08-07 | 1998-01-07 | Takeda Chemical Industries, Ltd. | Herstellung von Mikrokapseln, die wasserlösliche Arzneimittel enthalten |
| ATE153854T1 (de) * | 1992-12-16 | 1997-06-15 | Takeda Chemical Industries Ltd | Stabile pharmazeutische zubereitung mit fumagillolderivaten |
| US5290887A (en) * | 1993-04-30 | 1994-03-01 | The Dow Chemical Company | Epoxy resins containing thiadiazole and/or oxadiazole moieties |
| US5387657A (en) * | 1993-09-10 | 1995-02-07 | The Dow Chemical Company | Epoxy resins containing thiadiazole and/or oxadiazole moieties |
| EP0800385B1 (de) * | 1994-09-30 | 2000-12-20 | Takeda Chemical Industries, Ltd. | Oral anzuwendende arzneizubereitung mit verzögerter wirkstoffabgabe |
| US6117455A (en) * | 1994-09-30 | 2000-09-12 | Takeda Chemical Industries, Ltd. | Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent |
| US5710148A (en) * | 1995-03-06 | 1998-01-20 | Senju Pharmaceuticals Co., Ltd. | Corneal opacification inhibitory composition |
| US5837281A (en) | 1995-03-17 | 1998-11-17 | Takeda Chemical Industries, Ltd. | Stabilized interface for iontophoresis |
| CA2208336A1 (en) * | 1996-06-20 | 1997-12-20 | Hisamitsu Pharmaceuticals Co., Inc. | A device structure for iontophoresis |
| CA2210600A1 (en) * | 1996-07-17 | 1998-01-17 | Takashi Houkan | Inhibitor of tumor metastasis or recurrence |
| US5801012A (en) | 1996-09-17 | 1998-09-01 | Northwestern University | Methods and compositions for generating angiostatin |
| WO1998042722A1 (en) | 1997-03-21 | 1998-10-01 | President And Fellows Of Harvard College | Antisense inhibition of angiogenin expression |
| US6207704B1 (en) | 1997-06-09 | 2001-03-27 | Massachusetts Institute Of Technology | Type 2 methionine aminopeptidase [MetAP2] inhibitors and uses thereof |
| AU3980499A (en) | 1998-05-11 | 1999-11-29 | Endowment for Research in Human Biology, Inc., The | Use of neomycin for treating angiogenesis-related diseases |
| WO1999061432A1 (en) * | 1998-05-12 | 1999-12-02 | Biochem Pharma Inc. | Fumagillin analogs and their use as angiogenesis inhibitors |
| US8197430B1 (en) | 1998-05-22 | 2012-06-12 | Biopheresis Technologies, Inc. | Method and system to remove cytokine inhibitor in patients |
| US6620382B1 (en) | 1998-05-22 | 2003-09-16 | Biopheresis Technologies, Llc. | Method and compositions for treatment of cancers |
| US6537554B1 (en) | 1998-09-10 | 2003-03-25 | Curagen Corporation | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
| AU6409499A (en) | 1998-10-01 | 2000-04-17 | Children's Medical Center Corporation | Method of treatment of cardiovascular injuries |
| JP4414517B2 (ja) | 1999-09-01 | 2010-02-10 | 久光製薬株式会社 | イオントフォレーシス用デバイス構造体 |
| EP2087907B1 (de) | 1999-11-10 | 2014-09-24 | Innatus Corporation | Verfahren und System zum Entfernen von Zytokin-Inhibitor in Patienten |
| US6379708B1 (en) * | 1999-11-20 | 2002-04-30 | Cytologic, Llc | Method for enhancing immune responses in mammals |
| US7335650B2 (en) | 2000-01-14 | 2008-02-26 | Sterix Limited | Composition |
| US20030104573A1 (en) * | 2000-09-11 | 2003-06-05 | Shimkets Richard A. | Nucleotide sequences and amino acid sequences of secreted proteins involved in angiogenesis |
| US6919307B2 (en) | 2000-11-01 | 2005-07-19 | Praecis Pharmaceuticals, Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| US6548477B1 (en) | 2000-11-01 | 2003-04-15 | Praecis Pharmaceuticals Inc. | Therapeutic agents and methods of use thereof for the modulation of angiogenesis |
| US7105482B2 (en) | 2000-11-01 | 2006-09-12 | Praecis Pharmaceuticals, Inc. | Methionine aminopeptidase-2 inhibitors and methods of use thereof |
| EP1330447A2 (de) * | 2000-11-01 | 2003-07-30 | Praecis Pharmaceuticals Incorporated | Peptide als met-ap2-hemmer |
| ATE440094T1 (de) * | 2001-09-27 | 2009-09-15 | Equispharm Co Ltd | Fumagillolderivate und verfahren zu deren herstellung |
| US6803382B2 (en) | 2001-11-09 | 2004-10-12 | Galderma Research & Development, S.N.C. | Angiogenesis inhibitors and pharmaceutical and cosmetic use thereof |
| FR2832149B1 (fr) * | 2001-11-09 | 2006-01-06 | Galderma Res & Dev | Nouveaux inhibiteurs de l'angiogenese et leur utilisation pharmaceutique et cosmetique |
| WO2003086178A2 (en) * | 2002-04-11 | 2003-10-23 | Children's Medical Center Corporation | Methods for inhibiting vascular hyperpermeability |
| AU2003230852B2 (en) * | 2002-04-11 | 2008-07-10 | Children's Medical Center Corporation | TNP-470 polymer conjugates and use thereof |
| ES2449017T3 (es) * | 2002-06-21 | 2014-03-17 | The University Of Utah Research Foundation | Compuestos reticulados, y métodos de preparación y uso de los mismos |
| CN101137388A (zh) | 2003-05-15 | 2008-03-05 | 犹他卅大学研究基金会 | 抗粘连复合材料及其应用方法 |
| US20100330143A1 (en) | 2003-12-04 | 2010-12-30 | University Of Utah Research Foundation | Modified macromolecules and methods of making and using thereof |
| WO2005056608A1 (en) | 2003-12-04 | 2005-06-23 | University Of Utah Research Foundation | Modified macromolecules and methods of making and using thereof |
| EP1699812A2 (de) * | 2003-12-29 | 2006-09-13 | Praecis Pharmaceuticals Inc. | Inhibitoren von methioninaminopeptidase-2 und anwendungen davon |
| KR100552043B1 (ko) * | 2004-02-28 | 2006-02-20 | 주식회사종근당 | 푸마질롤 유도체를 포함하는 비만치료용 조성물 |
| WO2006002082A2 (en) * | 2004-06-16 | 2006-01-05 | Jack Arbiser | Carbazole formulations for the treatment of psoriasis and angiogenesis |
| WO2006084054A2 (en) * | 2005-02-02 | 2006-08-10 | Children's Medical Center Corporation | Method of treating angiogenic diseases |
| US20070065514A1 (en) | 2005-09-22 | 2007-03-22 | Howell Mark D | Method for enhancing immune responses in mammals |
| US8747870B2 (en) | 2006-04-20 | 2014-06-10 | University Of Utah Research Foundation | Polymeric compositions and methods of making and using thereof |
| CA2649915A1 (en) * | 2006-04-20 | 2007-11-01 | University Of Utah Research Foundation | Polymeric compositions and methods of making and using thereof |
| US20080032920A1 (en) * | 2006-07-11 | 2008-02-07 | Prestwich Glenn D | Macromolecules modified with electrophilic groups and methods of making and using thereof |
| US20080075690A1 (en) * | 2006-09-22 | 2008-03-27 | Mark Douglas Howell | Method for enhancing immune responses in mammals |
| US8399512B2 (en) * | 2007-11-28 | 2013-03-19 | Mersana Therapeutics, Inc. | Biocompatible biodegradable fumagillin analog conjugates |
| CA2731020A1 (en) | 2008-07-18 | 2010-01-21 | Zafgen, Inc. | Use of antiangiogenic fumagillins in the treatment of obesity |
| US8642650B2 (en) | 2008-12-04 | 2014-02-04 | Zafgen, Inc. | Methods of treating an overweight or obese subject |
| US20120004162A1 (en) | 2008-12-04 | 2012-01-05 | Vath James E | Methods of Treating an Overweight or Obese Subject |
| WO2013055385A2 (en) | 2011-10-03 | 2013-04-18 | Zafgen Corporation | Methods of treating age related disorders |
| WO2011044506A2 (en) | 2009-10-09 | 2011-04-14 | Zafgen Corporation | Sulphone compounds and methods of making and using same |
| KR20110039842A (ko) * | 2009-10-12 | 2011-04-20 | 주식회사 바이오씨에스 | 이미다졸 화합물을 유효성분으로 포함하는 안구의 혈관 신생 관련 질환의 예방 및 치료용 조성물 |
| WO2011085198A1 (en) | 2010-01-08 | 2011-07-14 | Zafgen Corporation | Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph) |
| AU2011204267B2 (en) | 2010-01-08 | 2015-12-03 | Zafgen Corporation | Fumagillol type compounds and methods of making and using same |
| US20130023513A1 (en) | 2010-01-12 | 2013-01-24 | Hughes Thomas E | Methods and Compositions for Treating Cardiovascular Disorders |
| US20130266578A1 (en) | 2010-04-07 | 2013-10-10 | Thomas E. Hughes | Methods of treating an overweight subject |
| WO2012012642A1 (en) | 2010-07-22 | 2012-01-26 | Zafgen Corporation | Tricyclic compounds and methds of making and using same |
| PH12013500934A1 (en) | 2010-11-09 | 2022-10-24 | Zafgen Inc | Crystalline solids of a metap-2 inhibitor and methods of making and using same |
| WO2012064928A1 (en) | 2010-11-10 | 2012-05-18 | Zafgen Corporation | Methods and compositions for treating thyroid hormone related disorders |
| WO2012074968A1 (en) | 2010-11-29 | 2012-06-07 | Zafgen Corporation | Methods of reducing risk of hepatobiliary dysfunction during rapid weight loss with metap-2 inhibitors |
| EP2646016B1 (de) | 2010-11-29 | 2017-05-17 | Zafgen, Inc. | Behandlung von fettleibigkeit mittels nicht-täglicher verabreichung von - 6 - 0 - (4 - dimethylaminoethoxy)-cinnamoylfumagillol |
| US9189078B2 (en) | 2010-12-20 | 2015-11-17 | Apple Inc. | Enhancing keycap legend visibility with optical components |
| KR20140006888A (ko) | 2011-01-26 | 2014-01-16 | 자프겐 인크. | 테트라졸화합물, 그리고, 이를 제조하는 방법 및 이를 이용하는 방법 |
| JP5876513B2 (ja) | 2011-03-08 | 2016-03-02 | ザフゲン，インコーポレイテッド | オキサスピロ［２．５］オクタン誘導体および類似体 |
| KR101979039B1 (ko) | 2011-05-06 | 2019-05-15 | 자프겐 인크. | 부분 포화된 삼환식 화합물 및 그리고 그의 제조방법 및 그를 이용하는 방법 |
| CN103748094B (zh) | 2011-05-06 | 2016-06-29 | 扎夫根股份有限公司 | 三环磺酰胺化合物及其制备和使用方法 |
| US9242997B2 (en) | 2011-05-06 | 2016-01-26 | Zafgen, Inc. | Tricyclic pyrazole sulphonamide compunds and methods of making and using same |
| WO2013010045A1 (en) | 2011-07-12 | 2013-01-17 | Biotime Inc. | Novel methods and formulations for orthopedic cell therapy |
| AU2013209719A1 (en) | 2012-01-18 | 2014-08-07 | Zafgen, Inc. | Tricyclic sulfone compounds and methods of making and using same |
| US9359369B2 (en) | 2012-01-18 | 2016-06-07 | Zafgen, Inc. | Tricyclic sulfonamide compounds and methods of making and using same |
| US9260419B2 (en) | 2012-05-07 | 2016-02-16 | Zafgen, Inc. | Polymorphic salt of a metap-2 inhibitor and methods of making and using same |
| CA2872876A1 (en) | 2012-05-08 | 2013-11-14 | Zafgen, Inc. | Treating hypothalamic obesity with metap2 inhibitors |
| EP2850079B1 (de) | 2012-05-09 | 2018-05-02 | Zafgen, Inc. | Fumigillol derivate,verfahren zu deren herstellung und deren verwendung |
| AU2013337288A1 (en) | 2012-11-05 | 2015-05-21 | Zafgen, Inc. | Tricyclic compounds for use in the treatment and/or control of obesity |
| EA028367B1 (ru) | 2012-11-05 | 2017-11-30 | Зафджен, Инк. | Способы лечения заболеваний печени |
| CA2890342A1 (en) | 2012-11-05 | 2014-05-08 | Zafgen, Inc. | Tricyclic compounds and methods of making and using same |
| CN105228610A (zh) | 2013-03-14 | 2016-01-06 | 扎夫根股份有限公司 | 治疗肾疾病和其它病症的方法 |
| TW201636342A (zh) | 2014-12-19 | 2016-10-16 | 武田藥品工業有限公司 | 煙黴醇衍生物 |
| AR105671A1 (es) | 2015-08-11 | 2017-10-25 | Zafgen Inc | Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso |
| CN106432255A (zh) | 2015-08-11 | 2017-02-22 | 扎夫根公司 | 烟曲霉素醇螺环化合物和制备和使用其的方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI830078L (fi) | 1982-01-15 | 1983-07-16 | Lilly Co Eli | Askorbinsyraetrar och liknande foereningar |
| JPH0629278B2 (ja) * | 1985-06-26 | 1994-04-20 | 藤沢薬品工業株式会社 | オキサスピロオクタン化合物 |
| JP2544136B2 (ja) | 1986-05-23 | 1996-10-16 | 第一製薬株式会社 | 硫酸化多糖体ｄｓ４１５２を含有する血管新生抑制剤及び抗腫瘍剤 |
| US5135919A (en) * | 1988-01-19 | 1992-08-04 | Children's Medical Center Corporation | Method and a pharmaceutical composition for the inhibition of angiogenesis |
| ES2059571T3 (es) * | 1988-01-19 | 1994-11-16 | Takeda Chemical Industries Ltd | Fumagilina como agente angiostatico. |
| US4954496A (en) * | 1988-08-12 | 1990-09-04 | Fujisawa Pharmaceutical Company, Ltd. | Cyclohexane derivatives and pharmaceutical compositions |
| PH26256A (en) * | 1988-08-12 | 1992-04-01 | Fujisawa Pharmaceutical Co | Oxaspiro [2,5] octane derivative |
| EP0357061B1 (de) * | 1988-09-01 | 1994-06-08 | Takeda Chemical Industries, Ltd. | Angiogenese hemmendes Mittel |
-
1989
- 1989-08-31 AT AT89116052T patent/ATE150750T1/de not_active IP Right Cessation
- 1989-08-31 DE DE68927904T patent/DE68927904T2/de not_active Expired - Lifetime
- 1989-08-31 EP EP95112110A patent/EP0682020A1/de not_active Withdrawn
- 1989-08-31 KR KR1019890012548A patent/KR0138530B1/ko not_active Expired - Fee Related
- 1989-08-31 ES ES89116052T patent/ES2099064T3/es not_active Expired - Lifetime
- 1989-08-31 EP EP89116052A patent/EP0359036B1/de not_active Expired - Lifetime
-
1992
- 1992-07-21 US US07/917,842 patent/US5698586A/en not_active Expired - Lifetime
-
1997
- 1997-06-11 GR GR970401389T patent/GR3023745T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0359036B1 (de) | 1997-03-26 |
| KR900004722A (ko) | 1990-04-12 |
| KR0138530B1 (ko) | 1998-05-15 |
| DE68927904D1 (de) | 1997-04-30 |
| US5698586A (en) | 1997-12-16 |
| GR3023745T3 (en) | 1997-09-30 |
| DE68927904T2 (de) | 1997-09-04 |
| EP0682020A1 (de) | 1995-11-15 |
| ES2099064T3 (es) | 1997-05-16 |
| EP0359036A1 (de) | 1990-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE150750T1 (de) | Fumagillol-derivate | |
| ATE119774T1 (de) | Imidazopyridinderivate und ihre verwendung. | |
| DK0486948T3 (da) | Forbindelser, der hæmmer retrovirale proteaser | |
| ES2088537T3 (es) | Derivados de piranil cianoguanidina. | |
| ATE126509T1 (de) | Disäuren von diarylstyrylchinolin. | |
| AU5476296A (en) | Sulfonamido substituted benzopyran derivatives | |
| DE69728761D1 (de) | Heterocyclisch substituierte benzolderivate und herbizide | |
| DE69027235D1 (de) | Xanthinderivate | |
| DE69022368D1 (de) | Quinolin-3-carboxanilid-derivate. | |
| NO902394D0 (no) | Fremgangsmaate for fremstilling av pyranyl-cyanoguanidin-derivater. | |
| CA2037975A1 (en) | 5-hydroxy-2,3-dihydrobenzofuran analogs as leukotriene biosynthesis inhibitors | |
| ATE122344T1 (de) | Naphthyloxazolidon-derivate. | |
| DK0641770T3 (da) | Hidtil ukendte forbindelser med blodpladeaggegationsinhiberende aktivitet | |
| ES2091489T3 (es) | Derivados de imidazol y composiciones farmaceuticas que los contienen. | |
| ES2093037T3 (es) | Derivados de beta-lactama y su preparacion. | |
| AU628592B2 (en) | Fungicides | |
| DE3587112D1 (de) | 2-quaternaer-pyridinalkylthio- oder -pyridinalkenylthiosubstituierte carbapeneme, diese enthaltende zusammensetzungen und ihre zusammenstellungen mit dhp-inhibitoren. | |
| HUT46511A (en) | Fungicides comprising pyridyl-cyclopropane-carboxamide derivatives as active ingredient | |
| EP1319658A4 (de) | Imidazolderivate oder ihre salze | |
| AU1246092A (en) | Oxoisoindoline phenyl derivatives of thiazolidine-2,4-dione | |
| ATE141918T1 (de) | Isoquinolinderivate | |
| TH5599A (th) | อนุพันธุ์ของคาร์บาโมอิลลอกซีไธโอฟีน |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| EELA | Cancelled due to lapse of time |